세계의 여성용 헬스케어 시장 예측 : 약제별, 유통 채널별, 용도별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Women Healthcare Market is accounted for $17.5 billion in 2023 and is expected to reach $50.1 billion by 2030 growing at a CAGR of 16.2% during the forecast period. It refers to the sector of healthcare services, products, and technologies specifically targeted towards addressing the unique healthcare needs and concerns of women across all age groups. This encompasses a wide range of medical areas, including reproductive health, maternal care, gynecological issues, breast health, menopause management, and various gender-specific conditions. Additionally, it encompasses diagnostic tools, screening tests, and treatments for conditions such as breast cancer, cervical cancer, osteoporosis, and other diseases that predominantly affect women.

According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over the age of 50. According to the WHO, in 2016, in developing countries such as Asia, Africa, and South America, there were around 21 million pregnancies among adolescent girls aged 15-19 years.

Market Dynamics:

Driver:

Increasing female population

As women constitute a substantial portion of the global population, their healthcare needs are diverse and complex, spanning across various life stages from adolescence to menopause and beyond. This demographic trend is prompting greater attention and investment in women's healthcare services and products tailored to address their unique physiological and medical requirements. Moreover, rising awareness about preventive care, advancements in medical technology, and initiatives aimed at promoting women's health are further fueling market expansion.

Restraint:

Financial constraints

Many women face economic challenges that limit their ability to afford healthcare, including routine check-ups, screenings, medications, and specialized treatments. Without adequate financial resources, women may delay seeking care or forego it altogether, leading to worsened health outcomes and increased healthcare disparities. However, the cost of health insurance and out-of-pocket expenses can be prohibitive, particularly for low-income individuals and those without comprehensive coverage.

Opportunity:

Women's empowerment and advocacy

With increasing awareness and emphasis on gender equality, women are taking charge of their health and demanding better access to healthcare services tailored to their specific needs. This empowerment has led to a surge in research and development focused on women's health issues, resulting in innovative treatments, diagnostics, and preventive measures. Furthermore, advocacy efforts have influenced policymakers to prioritize women's healthcare, leading to improved healthcare infrastructure and policies supporting women's reproductive rights, maternal health, and access to contraception.

Threat:

Reproductive rights and access to family planning

Legal and regulatory barriers, along with societal stigmas, can limit access to comprehensive reproductive healthcare services such as contraception, abortion, and prenatal care. Restrictions on reproductive rights not only impede women's ability to make informed choices about their reproductive health but also contribute to negative health outcomes, including unsafe abortions and maternal mortality. Additionally, disparities in access to family planning services disproportionately affect marginalized communities, exacerbating existing inequalities.

Covid-19 Impact:

While healthcare systems worldwide focused on managing the virus, routine women's health services faced disruptions, including preventive screenings, prenatal care, and access to contraceptives. Lockdown measures and overwhelmed healthcare facilities led to postponed appointments and decreased utilization of services, exacerbating existing health disparities. However, economic downturns disproportionately affected women, leading to reduced affordability and access to healthcare services. The shift towards telemedicine offered some continuity in care but also highlighted disparities in digital access and technology literacy, further impacting marginalized populations.

The actonel segment is expected to be the largest during the forecast period

As it is utilized for the prevention and treatment of osteoporosis, a condition characterized by reduced bone density and increased susceptibility to fractures, Actonel segment commanded the dominant share in the Women Healthcare market over the projected period. By offering an effective therapeutic option for osteoporosis management, Actonel helps to promote bone health and reduce the risk of fractures in women, thereby enhancing their overall well-being and quality of life. This segment's presence not only meets the medical needs of women but also contributes to raising awareness about osteoporosis and the importance of bone health, thus empowering women to take proactive measures for their health.

The endometriosis segment is expected to have the highest CAGR during the forecast period

Endometriosis segment is estimated to witness lucrative growth during the forecast period. Endometriosis, a disorder where tissue similar to the lining of the uterus grows outside the womb, affects millions of women globally, causing chronic pain and fertility issues. The heightened awareness and understanding of endometriosis have led to increased investments in developing advanced diagnostic tools, such as imaging techniques and biomarker assays, enabling early detection and personalized treatment strategies. Additionally, pharmaceutical companies are actively engaged in the development of novel drugs targeting the underlying mechanisms of endometriosis, offering patients more effective symptom management and potentially improving their quality of life.

Region with largest share:

Owing to the increased awareness and emphasis on preventive care and wellness have led to higher demand for women's health services and products, North America region commanded the largest share of the market over the prognosis period. Advancements in medical technology, particularly in areas such as gynecology, obstetrics, and reproductive health, have expanded treatment options and improved outcomes, further driving regional growth in the market. Moreover, supportive government initiatives, coupled with robust healthcare infrastructure and insurance coverage, have made healthcare more accessible to women across the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness substantial growth during the anticipated period as personalized medicine utilizes advanced technologies such as genetic testing, biomarker analysis and data analytics to customize healthcare strategies based on a patient's unique genetic makeup, lifestyle, and environmental factors. In women's healthcare, this approach enables more accurate diagnoses and targeted therapies for conditions like breast cancer, reproductive health disorders and hormonal imbalances. Furthermore, by optimizing treatment efficacy and minimizing adverse effects, personalized medicine not only improves patient outcomes but also enhances overall healthcare quality, making it a pivotal force driving growth in the market.

Key players in the market

Some of the key players in Women Healthcare market include Agile Therapeutics Inc, Allergan, Apothecus Pharmaceutical, Bayer AG, Blairex Laboratories, Ferring Pharmaceuticals, Lupin Limited, Mylan NV, Novartis AG and Pfizer Inc.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In September 2022, Lynparza was given clearance in China as the first line of maintenance therapy with bevacizumab for advanced ovarian cancer with homologous recombination deficit (HRD) positivity.

In January 2022, The women's hospital at Jackson Memorial, AdventHealth Celebration, and HCA Florida Healthcare's Medical Center using the Robotic surgical technology, Homins surgical system by Memic Innovative Surgery for gynecological procedures.

Drugs Covered:

• Actonel
• Forteo
• Mirena
• Nuvaring
• Ortho Tri-Cy Lo (28)
• Premarin
• Prolia
• Reclast/Aclasta
• Other Drugs

Distribution Channels Covered:

• Retail Pharmacies
• Online Providers
• Hospital Pharmacies

Applications Covered:

• Menopause
• Hormonal Infertility
• Postmenopausal Osteoporosis
• Endometriosis
• Contraceptives
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Women Healthcare Market, By Drug

• 5.1 Introduction
• 5.2 Actonel
• 5.3 Forteo
• 5.4 Mirena
• 5.5 Nuvaring
• 5.6 Ortho Tri-Cy Lo (28)
• 5.7 Premarin
• 5.8 Prolia
• 5.9 Reclast/Aclasta
• 5.10 Other Drugs

6 Global Women Healthcare Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Retail Pharmacies
• 6.3 Online Providers
• 6.4 Hospital Pharmacies

7 Global Women Healthcare Market, By Application

• 7.1 Introduction
• 7.2 Menopause
• 7.3 Hormonal Infertility
• 7.4 Postmenopausal Osteoporosis
• 7.5 Endometriosis
• 7.6 Contraceptives
• 7.7 Other Applications

8 Global Women Healthcare Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Agile Therapeutics Inc
• 10.2 Allergan
• 10.3 Apothecus Pharmaceutical
• 10.4 Bayer AG
• 10.5 Blairex Laboratories
• 10.6 Ferring Pharmaceuticals
• 10.7 Lupin Limited
• 10.8 Mylan NV
• 10.9 Novartis AG
• 10.10 Pfizer Inc